- Home
- » Tags
- » SGLT2 inhibitor
Top View
- Heart Failure and the Prognostic Impact and Incidence of New-Onset
- The New Class War: SGLT2 Inhibitors Versus DPP-4 Inhibitors
- Trends in Diabetes Medication Management CAPT Christopher Lamer, Pharmd, MHS, BCPS, CDE
- SGLT2) Inhibitor/Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Combination Agents
- Advancing Therapy in Suboptimally Controlled Basal Insulin–Treated
- DPP-4/SGLT2 Inhibitor Combined Therapy for Type 2 Diabetes
- Dapagliflozin
- SGLT2 Inhibitors As Potentially Helpful Drugs in PI3K Inhibitor-Induced
- Anatomical Classification Guidelines V2018 EPHMRA ANATOMICAL
- Insulin Glargine
- Therapeutic Class Overview Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
- FARXIGA Safely and Effectively
- Effects of Dapagliflozin And/Or Insulin Glargine on Beta Cell Mass And
- Ertugliflozin) Tablets, for Oral Use • Acute Kidney Injury and Impairment in Renal Function: Consider Initial U.S
- Key Considerations in Use of SGLT2 Inhibitors and GLP-1Ras for CV Risk Reduction in Patients with T2D
- Drug Interactions of Sglt2 Inhibitors (Gliflozins) Involving Ugt Enzymes Dr
- Emerging Roles of SGLT2 Inhibitors in Obesity and Insulin Resistance: Focus on Fat Browning and Macrophage Polarization
- Risks Vs Benefits for SGLT2 Inhibitor Medications
- The VERTIS CV Trial
- Canagliflozin Inhibits Interleukin-1Β-Stimulated Cytokine
- Effects of the SGLT2 Inhibitor Dapagliflozin on Energy
- Interaction of the Sodium/Glucose Cotransporter (SGLT)
- SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
- Patient Information on SGLT2 Inhibitors for Diabetes
- SGLT2 Inhibitors, What the Emergency Physician Needs to Know: a Narrative Review
- GLP-1 Agonists
- RFP) Significant Renal Protection Was Observed of Sglt2i Over Placebo2
- Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2
- Press Release
- SGLT2 Inhibitor Dapagliflozin Limits Podocyte Damage in Proteinuric Nondiabetic Nephropathy
- Antidiabetic Medication and Risk of Dementia in Patients with Type 2 Diabetes: a Nested Case–Control Study
- Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal
- Pharmacoepidemiological Study Protocol ER-9489 a Retrospective Nationwide Cohort Study to Investigate the Treatment of Type 2 Diabetic Patients in Finland - DAHLIA
- SGLT2 Inhibitors to Target Prediabetes in Adults: a Randomised, Double
- Medications for Hyperglycemia in Type 2 Diabetes and Review of Insulin Degludec and Dapagliflozin
- Canagliflozin) Tablets, for Oral Use Monitor for Signs and Symptoms During Therapy (5.2) Initial U.S
- Confidential: for Review Only Use of Sodium-Glucose Co-Transporter 2 Inhibitors and Risk of Serious Renal Events: Scandinavian Cohort Study
- DPP-4 Inhibitors Vs. SGLT-2 Inhibitors; Cons and Pros Xourgia E, Papazafiropoulou AK*, Karampousli E and Melidonis A
- SGLT2 Inhibitor Ipragliflozin Attenuates Breast Cancer Cell Proliferation
- SGLT2 Inhibitors Provide an Effective Therapeutic Option for Diabetes Complicated with Insulin Antibodies
- A Study of Newly Initiated Antidiabetic Medication in Primary Care in Region Uppsala
- Cost-Effectiveness of DPP-4 Inhibitor and SGLT2 Inhibitor Combination Therapy for Type 2 Diabetes
- SGLT2 Inhibitor Plus DPP-4 Inhibitor As Combination Therapy for Type 2 Diabetes: A
- Potential for Combination of Dipeptidyl Peptidase-4 Inhibitors and Sodium
- SGLT2 Inhibitors
- Comparison of the Efficacy and Safety of Once-Daily Insulin Degludec
- The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates
- A New Blood Glucose Management Algorithm for Type 2 Diabetes a Position Statement of the Australian Diabetes Society
- SGLT2 INHIBITORS Invokana
- Egfr Decline After SGLT2 Inhibitor Initiation: the Tortoise and the Hare Reimagined
- Steglatro (Ertugliflozin)